ArticleTranslational cancer research2022
Long non-coding RNA LINC02613 is a prognostic biomarker for breast cancer and correlates with the cell cycle and immune infiltration based on TCGA data.
Article in Translational cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- The multiple functions and mechanisms of long non-coding RNAs in regulating breast cancer progression.Frontiers in pharmacology · 2025Review
- Regulatory miRNAs, circRNAs and lncRNAs in cell cycle progression of breast cancer.Functional & integrative genomics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The development of transcriptomics has provided a new perspective to understand cancers. However, the role of long non-coding RNAs (lncRNAs) has not been fully elucidated. In the field of breast cancer, exploring the biological role and impact of lncRNAs on patient prognosis is of great importance. Methods: Expression data of the lncRNA, LINC02613, were downloaded from The Cancer Genome Atlas (TCGA) dataset. The Kruskal-Wallis rank sum test, Wilcoxon rank sum test and logistic regression analysis were used to investigate the relationship between LINC02613 and clinicopathological characteristics. Cox regression and Kaplan-Meier analyses were used to assess the prognostic value of LINC02613. Gene ontology (GO) analysis, gene set enrichment analysis (GSEA) and immune infiltration analysis were used to explore the potential biological mechanisms of LINC02613. Results: The expression of LINC02613 was downregulated in tumor samples and was related to poor overall survival (OS) in breast cancer patients. Statistical analysis revealed that low expression of LINC02613 was associated with Asian ethnicity, older age, higher histological grade and higher expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). Positive expression of immunohistochemical markers (ER, PR and HER2), high pathological stage and N stage were independent predictors for low LINC02613 expression. Decreased expression of LINC02613 caused an increase in Wnt2 and Wnt3 protein expression, which activated the Wnt signaling pathway, thereby promoting cell cycle progression, DNA replication and glycolysis. At the same time, the antitumor immunity of the body was also weakened when the expression of LINC02613 was decreased. Conclusions: Low expression of LINC02613 predicts poor OS in breast cancer patients. LINC02613 is involved in the regulation of the cell cycle, DNA replication and glycolysis via the Wnt signaling pathway, and it is related to antitumor immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.